Abstract
The selective κ opioid receptor agonist nalfurafine was launched in 2009 as an antipruritic drug for patients undergoing hemodialysis. It is the first clinically used compound with high selectivity for the κ opioid receptor. Nalfurafine had a different pharmacological feature from other κ opioid agonists. Nalfurafine induced neither addictive nor aversive effects, whereas other κ agonists such as U- 50,488H or salvinorin A produced psychotomimetic effects like dysphoria. Therefore, identification of the essential structural moieties of nalfurafine for binding to the κ opioid receptor was important for elucidation of the pharmacological discrepancies observed with these κ opioid agonists. Based on the investigations of various nalfurafine derivatives, the essential structural moieties of nalfurafine were unveiled. Both the nitrogen substituted by a cyclopropylmethyl group and the 6-amide side chain were indispensable. The phenol ring was important for obtaining strong binding affinities for the opioid receptors, but not indispensable for exerting selectivity for the κ receptor. This structure-activity information is expected to lead to the development of novel κ opioid receptor selective agonists.
Keywords: Opioid receptor, κ opioid receptor, agonist, nalfurafine, address part, U-50, 488H, active conformation.
Current Pharmaceutical Design
Title:Essential Structure of the κ Opioid Receptor Agonist Nalfurafine for Binding to the κ Receptor
Volume: 19 Issue: 42
Author(s): Hiroshi Nagase and Hideaki Fujii
Affiliation:
Keywords: Opioid receptor, κ opioid receptor, agonist, nalfurafine, address part, U-50, 488H, active conformation.
Abstract: The selective κ opioid receptor agonist nalfurafine was launched in 2009 as an antipruritic drug for patients undergoing hemodialysis. It is the first clinically used compound with high selectivity for the κ opioid receptor. Nalfurafine had a different pharmacological feature from other κ opioid agonists. Nalfurafine induced neither addictive nor aversive effects, whereas other κ agonists such as U- 50,488H or salvinorin A produced psychotomimetic effects like dysphoria. Therefore, identification of the essential structural moieties of nalfurafine for binding to the κ opioid receptor was important for elucidation of the pharmacological discrepancies observed with these κ opioid agonists. Based on the investigations of various nalfurafine derivatives, the essential structural moieties of nalfurafine were unveiled. Both the nitrogen substituted by a cyclopropylmethyl group and the 6-amide side chain were indispensable. The phenol ring was important for obtaining strong binding affinities for the opioid receptors, but not indispensable for exerting selectivity for the κ receptor. This structure-activity information is expected to lead to the development of novel κ opioid receptor selective agonists.
Export Options
About this article
Cite this article as:
Nagase Hiroshi and Fujii Hideaki, Essential Structure of the κ Opioid Receptor Agonist Nalfurafine for Binding to the κ Receptor, Current Pharmaceutical Design 2013; 19 (42) . https://dx.doi.org/10.2174/138161281942140105165011
DOI https://dx.doi.org/10.2174/138161281942140105165011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
Current Pharmaceutical Design Characterization of Phosphorylated Proteins Using Mass Spectrometry
Current Protein & Peptide Science Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry
Current Drug Targets Cannabinoids: Occurrence and Medicinal Chemistry
Current Medicinal Chemistry Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease
Recent Patents on CNS Drug Discovery (Discontinued) <i>In-Silico</i> Validation and Fabrication of Matrix Diffusion-Based Polymeric Transdermal Patches for Repurposing Gabapentin Hydrochloride in Neuropathic Pain
CNS & Neurological Disorders - Drug Targets The Significant Role of Nutraceutical Compounds in Ulcerative Colitis Treatment
Current Medicinal Chemistry Therapeutic Potential of Nitrate Esters of Commonly Used Drugs
Current Topics in Medicinal Chemistry Design of Phenotypic Screens for Bioactive Chemicals and Identification of their Targets by Genetic and Proteomic Approaches
Combinatorial Chemistry & High Throughput Screening Infertility, Pregnancy Loss and Adverse Birth Outcomes in Relation to Maternal Secondhand Tobacco Smoke Exposure
Current Women`s Health Reviews Concept of Comprehensive Treatment for Osteoarthritis (OA)
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Stimuli-responsive Drug Delivery Nanosystems: From Bench to Clinic
Current Nanomedicine Bioinformatic Approaches in Glycomics and Glycoproteomics
Current Proteomics Advances in Anti-inflammatory Activity, Mechanism and Therapeutic Application of Ursolic Acid
Mini-Reviews in Medicinal Chemistry Evaluation of a Reporter Gene Assay for Bioactivity Determination of Therapeutic Interferons through a Collaborative Study
Current Pharmaceutical Analysis Electrochemical Detection and Sensing of Reactive Oxygen Species
Current Organic Chemistry Synthesis of 3-phenyl-4-phenylvinyl Benzopyranones and the Corresponding 2,2-dimethyl-benzopyrans with Structural Similarity to Estradiol, as Estrogen Receptor Ligands
Medicinal Chemistry The Chemistry and Pharmacology of Genistein
The Natural Products Journal Design, Synthesis and Antitumor Activity of Novel Cis-Furoquinoline Derivatives
Letters in Drug Design & Discovery A High Throughput Fluorescence Polarization Assay for Inhibitors of the GoLoco Motif/G-alpha Interaction
Combinatorial Chemistry & High Throughput Screening